Company: SRPT
Filing Date: 2025-07-16
Form Type: 8-K
Source: 0000950170-25-096257
Chunk: 3

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-07-16
Form: 8-K
Item: Item 5.02
Chunk 3
---
 Agreement, the Company has agreed to pay Mr. Murray severance in the lump sum amount of $549,272.80, as well as a consulting fee of $400 per hour for the consulting services provided. The Company thanks Mr. Murray for his substantial contributions during a transformational period for the Company and wishes him well.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Forward Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the safe harbor provisions of the U. S. Private Securities Litigation Reform Act of 1995. Any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “expects,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the Company’s reduction in workforce, including the costs or charges that the Company may incur in connection with the reduction in force and expected financial results. Forward-looking statements also include those regarding Sarepta’s future business developments and actions and the timing of the same.

These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the reduction in force may take longer or result in more significant charges or cash expenditures than anticipated or otherwise negatively impact the Company and its business plans during and after the period during which the reduction in force is being executed; the estimates and judgments the Company makes, or the assumptions on which it relies, in preparing its consolidated financial statements could prove inaccurate; and those risks identified under the heading “ Risk Factors” in Sarepta’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), as well as other SEC filings made by the Company which you are encouraged to review.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit      Description                                                                                                                              
                                                                                                                                                        
   Number                                                                                                                                               
     99.1      Press Release dated July 16, 2025                                                                                                        
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────